Insights - The long-awaited September meeting of the FOMC takes place this coming Thursday. Market participants are unusually attuned to this particular meeting due to the ongoing … Continue Reading
Read NowInsights - After repeat attempts to convince the U.S. FDA that the company should not be required to run another clinical trial, it appears AcelRx Pharmaceuticals (ACRX) may have finally … Continue Reading
Read NowInsights - After the last two weeks, everyone’s ready for a 3-day break. August closed out with the S&P 500 down 6%, and the NASDAQ Biotech Index … Continue Reading
Read NowInsights - The U.S. FDA has filed Sarepta Therapeutics’ (SRPT) eteplirsen New Drug Application, starting the clock on a 6-month review of the drug. The FDA will make an … Continue Reading
Read NowInsights - Gilead Sciences (GILD) reported a blowout quarter on Tuesday afternoon, topping consensus estimates across the board and possibly stopping the bleeding — at least temporarily — … Continue Reading
Read NowInsights - Second quarter earnings from the large, publicly traded biopharma and specialty pharma companies begin to trickle out on Thursday, July 23. Below is your cheat sheet … Continue Reading
Read NowInsights - Healthcare investors can sleep easy tonight with one of 2015’s major unanswered questions now off the table. Celgene (CELG) will buy Receptos (RCPT) for $7.2 billion, or $232 in … Continue Reading
Read Now
